Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a ...

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical ...